The patients pharma forgot.

You've tried Zyrtec. Still breaking out. Your allergist has a 3-month wait, your derm punted you to immunology, and the ER doesn't know what to do with hives. FlareDown is the structured next step you've been missing.

Your Itch Score
0 / 42
UAS7 — the standard metric for urticaria activity
Well-controlled Severe
1 AI intake — your history, synthesized
2 Licensed clinician reviews & prescribes
3 Monthly check-ins, tracked over time

CSU affects roughly 1% of the population. Most fail the standard dose of a second-generation antihistamine. The guidelines say up-titrate to 4x. Almost nobody does it. Then what?

3–6 months
Average wait to see an allergist in the US
<50%
Of patients respond to standard-dose antihistamines
0
AI-native managed CSU clinics — anywhere

How it works

Adaptive intake

An AI conversation that walks through your symptom history, prior treatments, triggers, and current medications. Clinically interactive — meets the standard for intake, and surfaces everything the clinician needs to make a real decision.

Clinician review

A licensed allergist or dermatologist reviews your intake, asks follow-up questions async, and makes a prescribing decision. The AI prepares the case; the clinician decides. No guessing, no rushed in-person visits.

Monthly check-in

Every month, you complete a UAS7 tracker. Your score gets logged, compared to last month, and reviewed by your clinician. If you're not improving, the protocol escalates. If you are, you stay the course. You always know where you stand.

No one follows the protocol.
We do.

Every patient gets the guideline-backed progression — not whoever shouts the loudest, not a one-size-fits-all script. The protocol is baked into the product. AI monitors your UAS7 score each cycle and flags when escalation criteria are met.

Step 1 — Antihistamine optimization
Up-titrate to 4x second-gen antihistamine. Most patients never get here. We start here.
Step 2 — Add-on agents
Montelukast, H2 blocker, hydroxyzine, doxepin — sequenced based on response
Step 3 — Biologic pathway
Xolair, Dupixent — with prior-auth navigation, covered through our clinical partners

Outcomes are the product

We track every patient's UAS7 score every month. That's not a feature — it's the foundation. The data tells us when you're progressing, when to escalate, and eventually, which sequence works for which patient profile. That's how the product gets better. That's the moat.

UAS7 tracked monthly

The validated urticaria activity score, every cycle, without fail

Longitudinal record

Your full treatment history, accessible to you and your clinician, grows over time

Aggregate intelligence

Treatment sequences that work for similar patients — built from real outcomes, not guidelines

Clinician-supervised

Built on the right guardrails

PHI handling, clinical intake, diagnosis, and prescribing run on HIPAA-compliant infrastructure. A licensed clinician makes every clinical decision. The AI prepares and surfaces; the clinician decides. We screen for red flags — angioedema and anaphylaxis go to urgent care, not async care.

Licensed clinician in every prescribing decision
HIPAA-compliant infrastructure throughout
Red flag screening — urgent cases directed to emergency care
Non-controlled substances only

Still breaking out on Zyrtec?
We know what comes next.

Pharma flooded the market with new molecules. Care delivery stayed broken. FlareDown is the infrastructure that connects them — AI-managed, clinician-supervised, and built around your UAS7 score from day one.

If you've been stuck, cycling through doctors who don't know what to do next — that's the gap. We built FlareDown to close it.